BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

924 related articles for article (PubMed ID: 33542230)

  • 1. Prostate cancer.
    Rebello RJ; Oing C; Knudsen KE; Loeb S; Johnson DC; Reiter RE; Gillessen S; Van der Kwast T; Bristow RG
    Nat Rev Dis Primers; 2021 Feb; 7(1):9. PubMed ID: 33542230
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
    Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
    Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate Cancer Review: Genetics, Diagnosis, Treatment Options, and Alternative Approaches.
    Sekhoacha M; Riet K; Motloung P; Gumenku L; Adegoke A; Mashele S
    Molecules; 2022 Sep; 27(17):. PubMed ID: 36080493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of Concomitant Androgen Deprivation Therapy in Patients Treated with Early Salvage Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: Long-term Results from a Large, Multi-institutional Series.
    Gandaglia G; Fossati N; Karnes RJ; Boorjian SA; Colicchia M; Bossi A; Seisen T; Cozzarini C; Di Muzio N; Noris Chiorda B; Zaffuto E; Wiegel T; Shariat SF; Goldner G; Joniau S; Battaglia A; Haustermans K; De Meerleer G; Fonteyne V; Ost P; Van Poppel H; Montorsi F; Briganti A
    Eur Urol; 2018 Apr; 73(4):512-518. PubMed ID: 29229176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential Risk of Castration Resistance After Initial Radical Prostatectomy or Radiotherapy for Prostate Cancer.
    Obata H; Shiota M; Akitake N; Takeuchi A; Kashiwagi E; Dejima T; Kiyoshima K; Inokuchi J; Tatsugami K; Eto M
    Anticancer Res; 2017 Oct; 37(10):5631-5637. PubMed ID: 28982880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mortality and Androgen Deprivation Therapy as Salvage Treatment for Biochemical Recurrence after Primary Therapy for Clinically Localized Prostate Cancer.
    Fu AZ; Tsai HT; Haque R; Yood MU; Cassidy-Bushrow AE; Van Den Eeden SK; Keating NL; Smith MR; Zhou Y; Aaronson DS; Potosky AL
    J Urol; 2017 Jun; 197(6):1448-1454. PubMed ID: 28007467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
    Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
    Actas Urol Esp; 2011; 35(10):565-79. PubMed ID: 21757258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer.
    Cornford P; Bellmunt J; Bolla M; Briers E; De Santis M; Gross T; Henry AM; Joniau S; Lam TB; Mason MD; van der Poel HG; van der Kwast TH; Rouvière O; Wiegel T; Mottet N
    Eur Urol; 2017 Apr; 71(4):630-642. PubMed ID: 27591931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Obesity is associated with castration-resistant disease and metastasis in men treated with androgen deprivation therapy after radical prostatectomy: results from the SEARCH database.
    Keto CJ; Aronson WJ; Terris MK; Presti JC; Kane CJ; Amling CL; Freedland SJ
    BJU Int; 2012 Aug; 110(4):492-8. PubMed ID: 22094083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abiraterone acetate plus prednisone in non-metastatic biochemically recurrent castration-naïve prostate cancer.
    Spetsieris N; Boukovala M; Alafis I; Davis J; Zurita A; Wang X; Tu SM; Chapin BF; Aparicio A; Corn P; Wang J; Subudhi SK; Araujo J; Papadopoulos J; Pruitt L; Weldon JA; Logothetis CJ; Efstathiou E
    Eur J Cancer; 2021 Nov; 157():259-267. PubMed ID: 34536949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of Androgen Deprivation Therapy and Salvage Radiotherapy versus Salvage Radiotherapy Alone for Recurrent Prostate Cancer after Radical Prostatectomy.
    Yoo S; You D; Kim YS; Hong JH; Ahn H; Kim CS
    Urol Int; 2017; 99(4):406-413. PubMed ID: 29020683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment failure and clinical progression after salvage therapy in men with biochemical recurrence after radical prostatectomy: radiotherapy vs androgen deprivation.
    Song C; Kim YS; Hong JH; Kim CS; Ahn H
    BJU Int; 2010 Jul; 106(2):188-93. PubMed ID: 20002666
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How can we best manage biochemical failure after radical prostatectomy?
    Kim WT; Kim J; Kim WJ
    Investig Clin Urol; 2022 Nov; 63(6):592-601. PubMed ID: 36347548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of androgen deprivation and salvage radiation therapy for patients with prostate cancer and biochemical recurrence after prostatectomy.
    Ghadjar P; Aebersold DM; Albrecht C; Böhmer D; Flentje M; Ganswindt U; Höcht S; Hölscher T; Sedlmayer F; Wenz F; Zips D; Wiegel T;
    Strahlenther Onkol; 2018 Jul; 194(7):619-626. PubMed ID: 29383406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes and Prognostic Factors in Men Receiving Androgen Deprivation Therapy for Prostate Cancer Recurrence after Radical Prostatectomy.
    Ravi P; Karnes RJ; Rangel LJ; Pagliaro LC
    J Urol; 2018 Nov; 200(5):1075-1081. PubMed ID: 29709664
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Upfront androgen deprivation therapy with salvage radiation may improve biochemical outcomes in prostate cancer patients with post-prostatectomy rising PSA.
    Jang JW; Hwang WT; Guzzo TJ; Wein AJ; Haas NB; Both S; Vapiwala N
    Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):1493-9. PubMed ID: 22401922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
    Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; Van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
    Eur Urol; 2011 Apr; 59(4):572-83. PubMed ID: 21315502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brain metastasis in a patient with BRCA2-mutated treatment-related neuroendocrine prostate carcinoma and long-term response to radiotherapy and Olaparib: A case report and literature review.
    Uehara R; Obinata D; Hashimoto S; Nakahara K; Uchida H; Yoshizawa T; Mochida J; Yamaguchi K; Sakaguchi M; Ozawa Y; Mori F; Miura K; Ishige T; Masuda S; Nakayama T; Takahashi S
    Medicine (Baltimore); 2024 Mar; 103(9):e37371. PubMed ID: 38428891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimal PSA Threshold for Androgen-Deprivation Therapy in Patients with Prostate Cancer following Radical Prostatectomy and Adjuvant Radiation Therapy.
    Ahn HK; Lee KS; Kim D; Rha KH; Hong SJ; Chung BH; Koo KC
    Yonsei Med J; 2020 Aug; 61(8):652-659. PubMed ID: 32734728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of Biochemical Recurrence after Primary Curative Treatment for Prostate Cancer: A Review.
    Artibani W; Porcaro AB; De Marco V; Cerruto MA; Siracusano S
    Urol Int; 2018; 100(3):251-262. PubMed ID: 29161715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 47.